Roche Targets 89bio’s Fatty Liver Therapy – Merger Arbitrage Mondays

Sep 22, 2025

∙ Paid

89bio, Inc. (ETNB): $14.87

Market Cap: $2.21B

Deal value: $2.4B

Roche entered a merger agreement on September 18, 2025, to acquire biotech company 89bio in a deal valued at $2.4 billion, aiming to strengthen its drug pipeline by acquiring an experimental treatment for obesity-related liver disease. The deal would help Roche expand in an area linked to the …

Keep reading with a 7-day free trial

Subscribe to The Special Situation Report to keep reading this post and get 7 days of free access to the full post archives.